Salvage therapy with single agent bendamustine for recurrent glioblastoma

Chamberlain, Marc; Johnston, Sandra
December 2011
Journal of Neuro-Oncology;Dec2011, Vol. 105 Issue 3, p523
Academic Journal
The treatment of recurrent glioblastoma (GBM) remains challenging notwithstanding the recent approval of bevacizumab for this indication. Bendamustine has a bifunctional mechanism of action including alkylation, penetrates the CNS and does not show cross resistance to other alkylator chemotherapies. In a single institution phase 2 trial, patients with recurrent GBM were treated with bendamustine (100 mg/m/day administered intravenously for two consecutive days every 4 weeks). The primary study endpoint was 6-month progression free survival (PFS-6). An interim analysis for futility was conducted according to a Simon two-stage minimax design. Complete blood counts were obtained bimonthly, clinical evaluations and brain imaging every month for the first cycle and bimonthly thereafter. Treatment responses were based upon MacDonald criteria. Sixteen patients were enrolled (nine men; seven women), with a median age of 53 years (range 36-68) and a median Karnofsky performance status of 90 (range 70-100). Nine patients were treated at first relapse and seven at second relapse (five patients were bevacizumab failures). A total of 25 cycles of bendamustine were administered with a median of 1 (range 1-6). Bendamustine-related toxicity was seen in eight patients; lymphopenia in seven (5 grade 3; 2 Grade 4), thrombocytopenia in two (1 Grade 3; 1 Grade 4), and neutropenia in one (1 Grade 3). Fourteen patients have died due to disease progression, two patients are alive and on alternative therapies. Only one patient was progression-free at 6 months, triggering the stopping rule for futility. Bendamustine was reasonably well tolerated but failed to meet the study criteria for activity in adults with recurrent GBM.

Tags: GLIOMAS -- Treatment;  CANCER -- Chemotherapy;  SALVAGE therapy;  BEVACIZUMAB;  DRUGS -- Administration;  DISEASE progression;  CLINICAL trials


Related Articles

  • The Role of Integrins in Glioma Biology and Anti-Glioma Therapies. Tabatabai, Ghazaleh; Tonn, J�rg-Christian; Stupp, Roger; Weller, Michael // Current Pharmaceutical Design;8/1/2011, Vol. 17 Issue 23, p2402 

    The tumor environment is critical for tumor maintenance and progression. Integrins are a large family of cell surface receptors mediating the interaction of tumor cells with their microenvironment and play important roles in glioma biology, including migration, invasion, angiogenesis and tumor...

  • An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma. Alona Muzikansky; Karly David; Mary Gerard; M. McNamara; Phuong Phan; Ainsley Ross // Journal of Neuro-Oncology;Apr2009, Vol. 92 Issue 2, p149 

    Abstract��Recent clinical trial results suggest that anti-angiogenic therapy may be effective against recurrent malignant glioma. Though these treatments prolong progression-free survival, the extent to which they prolong overall survival is unknown. We pooled data from 34 patients...

  • Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials. Loupakis, Fotios; Bria, Emilio; Vaccaro, Vanja; Cuppone, Federica; Milella, Michele; Carlini, Paolo; Cremolini, Chiara; Salvatore, Lisa; Falcone, Alfredo; Muti, Paola; Sperduti, Isabella; Giannarelli, Diana; Cognetti, Francesco // Journal of Experimental & Clinical Cancer Research (17569966);2010, Vol. 29, p58 

    Background: Although the addition of bevacizumab to 1st line chemotherapy provides a significant survival benefit for advanced colorectal cancer, the magnitudes of both advantages and toxicities have not been extensively investigated. Methods: A literature-based meta-analysis was conducted;...

  • Re-irradiation with and without bevacizumab as salvage therapy for recurrent or progressive high-grade gliomas. Hundsberger, Thomas; Brügge, Detlef; Putora, Paul; Weder, Patrik; Weber, Johannes; Plasswilm, Ludwig // Journal of Neuro-Oncology;Apr2013, Vol. 112 Issue 1, p133 

    The optimal treatment for recurrent high-grade gliomas is unknown and a standard of care does not exist. Re-irradiation with concomitant bevacizumab represents an option. Retrospectively, we analyzed a cohort of heavily pretreated patients ( n = 14) with relapsing HGGs who underwent...

  • Paclitaxel in combination with carboplatin as salvage treatment in patients with castration-resistant prostate cancer: a Hellenic oncology research group multicenter phase II study. Kentepozidis, N.; Soultati, A.; Giassas, S.; Vardakis, N.; Kalykaki, A.; Kotsakis, A.; Papadimitraki, E.; Pantazopoulos, N.; Bozionellou, V.; Georgoulias, V. // Cancer Chemotherapy & Pharmacology;Jul2012, Vol. 70 Issue 1, p161 

    Introduction: To evaluate the efficacy and tolerance of biweekly paclitaxel and carboplatin combination in patients with castration-resistant prostate cancer. Patients and methods: Patients were treated with paclitaxel at the dose of 135 mg/m followed by carboplatin AUC 3 on day 1 every 2 weeks...

  • Salvage treatment in metastatic breast cancer with weekly paclitaxel and bevacizumab. Polyzos, Aris; Kalbakis, Kostas; Kentepozidis, Nikolaos; Giassas, Stylianos; Kalykaki, Antonia; Vardakis, Nikolaos; Bozionelou, Vasiliki; Saloustros, Emmanouel; Kontopodis, Emmanouel; Georgoulias, Vassilis; Mavroudis, Dimitris // Cancer Chemotherapy & Pharmacology;Jul2011, Vol. 68 Issue 1, p217 

    Background: Weekly paclitaxel (P) in combination with bevacizumab (B) is an effective regimen as initial treatment of metastatic breast cancer (MBC). We investigated in a phase II study the activity of the same regimen as salvage therapy in MBC. Methods: Pretreated women with MBC received weekly...

  • Large volume reirradiation as salvage therapy for glioblastoma after progression on bevacizumab. Magnuson, William; Ian Robins, H.; Mohindra, Pranshu; Howard, Steven // Journal of Neuro-Oncology;Mar2014, Vol. 117 Issue 1, p133 

    Outcomes after bevacizumab failure for recurrent glioblastoma (GBM) are poor. Our analysis of 16 phase II trials ( n = 995) revealed a median overall survival (OS) of 3.8 months (±1.0 month SD) after bevacizumab failure with no discernible activity of salvage chemotherapy. Thus, the optimal...

  • Ovarian Cancer Drug Slows Disease Progression.  // Healthy Years;Mar2012, Vol. 9 Issue 3, p4 

    The article the findings of a study on an ovarian cancer drug that can slow disease progression. The study included women diagnosed with Stage III or IV ovarian cancer who had undergone surgery. It divided the women into three treatment groups, one that received bevacizumab for cycles 2 through...

  • Bevacizumab and oral metronomic cyclophosphamide in platinum-resistant ovarian cancer. Pujade-Lauraine, Eric // Journal of Gynecologic Oncology;Jul2013, Vol. 24 Issue 3, p209 

    The author reflects on the effectiveness of oral metronomic cyclophosphamide (OMC) and bevacizumab against recurrent ovarian cancer. He says that bevacizumab has response rate ranging from 16%-21% if used as a single-agent drug, in which randomized trials have shown improved progression-free...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics